Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Published:2024-03-03 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Cassanello Giulio¹²,Luna de Abia Alejandro¹³,Falchi Lorenzo⁴

Affiliation:

1. Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, USA

2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

3. Hematology Service, Hospital Universitario Ramon y Cajal, Madrid, Spain

4. Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, USA

Funder

Associazione italiana contro le leucemie-linfomi e mieloma

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2321648

Reference70 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study

3. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

4. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

5. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data;International Journal of Molecular Sciences;2024-09-09

2. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

3. Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL);International Journal of Molecular Sciences;2024-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3